Saquinavir: A review of its use in boosted regimens for treating HIV infection

Drugs

Volumn 63, Issue 12, 2003, Pages 1299-1324

  Plosker, Greg L ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Boosted regimens; Drug interactions; HIV infection; Pharmacodynamics; Pharmacoenhancement; Pharmacokinetic enhancement; Pharmacokinetics; Saquinavir; Therapeutic use; Tolerability

Indexed keywords

ATAZANAVIR; CD4 ANTIGEN; CYTOCHROME P450 3A4; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LIPID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; CELL COUNT; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER TOXICITY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; T LYMPHOCYTE; VIRUS LOAD; VOMITING;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; METABOLIC CLEARANCE RATE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0038575809     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363120-00007     Document Type: Review

References (99)

1. Figgitt DP, Plosker GL. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs 2000 Aug; 60 (2): 481-516
2. Perry CM, Noble S. Saquinavir soft-gel capsule formulation: a review of its use in patients with HIV infection. Drugs 1998 Mar; 55 (3): 461-86
3. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52 (1): 93-112
4. Moyle GJ. Saquinavir-soft gel: establishing saquinavir in HAART regimens. Expert Opin Invest Drugs 1998; 7 (8): 1313-22
5. Gill J, Feinberg J. Saquinavir soft gelatin capsule: a comparative safety review. Drug Saf 2001; 24 (3): 223-32
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997 Sep 11; 337: 725-33
7. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Advanced HIV Disease Ritonavir Study Group. Lancet 1998 Feb 21; 351 (9102): 543-9
8. Haubrich R, Lalezari J, Follansbee SE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33-42
9. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001 Apr; 2 (2): 105-13
10. British HIV Association (BHIVA). British HIV Association Guidelines [online]. Available from URL: http://www.bhiva.org/guidelines.htm [Accessed 2003 Feb 20]
11. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Reader 2001; 11 (2): 87-98
12. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999 Feb; 20: 147-69
13. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11
14. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997 Aug; 44 (2): 190-4
15. Hoffmann-La Roche Inc. Fortovase® (saquinavir) soft gelatin capsules - complete product information [online]. Available from URL: http://www.rocheusa.com/products/fortovase/pi.html [Accessed 2002 Oct 30]
16. Molla A, Mo H, Vasavanonda S, et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 2002 Jul; 46 (7): 2249-53
17. Para MF, Glidden DV, Coombs RW, et al. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clinical Trials Group protocol 333. J Infect Dis 2000 Sep; 182 (3): 733-43
18. Schmidt B, Walter H, Moschik B, et al. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 2000; 14: 1731-8
19. Valet L, de Mendoza C, González de Requena D, et al. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002; 16 (14): 1964-6
20. Barreiro P, Camino N, de Mendoza C, et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Int J Antimicrob Agents 2002; 20: 438-43
21. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001; 15: 609-15
22. Hsu A, Granneman GR, Cao G. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63 (4): 453-64
23. Merry C, Barry MG, Mulcahy F, et al: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997 Mar 15; 11 (4): F29-33
24. Buss N, Snell P, Bock J, et al. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52: 255-64
25. Gisolf EH, van Heeswijk RPG, Hoetelmans RWM, et al. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 2000; 14: 801-5
26. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44 (10): 2672-8
27. Kurowski M, Müller M, Donath F, et al. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir. Eur J Med Res 1999 Mar 26; 4 (3): 101-4
28. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Medicine 2002 Apr; 3 (2): 97-104
29. Cardiello PG, van Heeswijk RP, Hassink EA, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002 Apr 15; 29 (5): 464-70
30. Hoffmann-La Roche Inc. Invirase® (saquinavir mesylate) capsules - complete product information [online]. Available from URL: http://www.rocheusa.com/products/invirase/pi.html [Accessed 2002 Oct 30]
31. Kurowski M, Sternfeld T, Hill A, et al. Comparative pharmacokinetics and short-term safety of Fortovase/ritonavir and Invirase/ritonavir 1000mg/100mg bid [abstract/poster no. S29e]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle
32. Cardiello P, Ananworanich J, Monhaphol T, et al. Pharmacokinetics of once daily saquinavir-hard gel caps and saquinavir-soft gel caps boosted with ritonavir in HIV-1+ Thai patients [abstract no. MoPpB2007]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, 32
33. Kurowski M, Sternfeld T, Sawyer AW, et al. Minor interaction between efavirenz and saquinavir, when combined with small doses of ritonavir in a q.d. regimen. Roche. 2002. (Data on file)
34. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999 Jul 30; 13 (11): F71-7
35. Kurowski M, Arslan A, Arasteh K, et al. Comparative pharmacokinetics of twice daily (BID) Fortovase/ritonavir and Invirase/ritonavir [poster no. FOR062]. 8th Deutscher AIDS Kongress; 2002 Jul 4-7; Berlin
36. van Heeswijk RPG, Veldkamp AI, Mulder JW, et al. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: A pharmacokinetic pilot study. AIDS 2000; 14 (9): F103-10
37. Veldkamp AI, van Heeswijk RPG, Mulder JW, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J AIDS 2001; 27: 344-9
38. Acosta EP, Zorrilla C, Bardeguez A, et al. pharmacokinetics (PK) of saquinavir/ritonavir (SQV/RTV) in HIV-infected pregnant women [abstract no. A-1405]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 22
39. Landman R, Peytavin G, Lamotte C, et al. Saquinavir (SQV) plasma and intracellular concentrations in a once daily dosing combination fortovase (SQV-SGC) - low dose ritonavir (RTV) in a prospective study (IMEA 015) in HIV-infected patients (pts) [abstract no. 179]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8-11; Buenos Aires
40. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz; pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy [letter]. J. Acquir. Immune. Defic. Syndr. 2003 Feb 1; 32 (2): 240-2
41. Mallolas J, Blanco J, Sarasa M, et al. Intensification therapy with saquinavir soft gel (SSG)/ritonavir (RIV) QD in patients failing on a saquinavir hard gel (SHG) containing HAART [abstract no. 675]. 1st International Aids Society Conference; 2001 Jul 8-11; Buenos Aires, 282
42. Hellinger J, Morris AB, Piscitelli S, et al. Pilot study of saquinavir-SGC (Fortovase, AQV) 1000 mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ) [poster no. 451-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle
43. Smith GHR, Klein M, Leblanc R, et al. Salvage therapy for HIV-1 infection with lopinavir/ritonavir (LOP/RIT), saquinavir-SGC (SQR), and nucleoside analogues in patients having failed all three antiretroviral classes [abstract no. 212]. Can J Infect Dis 2001; 12 Suppl. B: 29B
44. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 Suppl. 1: S5-37
45. Stephan C, von Hentig N, Moesch M, et al. Saquinavir plasma exposure is not decreased in lopinavir/ritonavir co-administration compared to standard ritonavir booster by AUC in steady state condition [poster]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow
46. SQV/LPV/r has a favourable PK profile making it a logical choice for double boosting. Reports from the 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow. Roche, 2002. (Data on file)
47. Ribera E, Lopez RM, Pou L, et al. Pharmacokinetics of a double boosting regimen of lopinavir, plus minidose ritonavir, plus saquinavir in HIV-infected adults [poster no. TuPeB4545]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona
48. Corbett AH, Eron JJ, Diebold M, et al. A triple protease inhibitor [PI] salvage regimen of amprenavir [APV] + saquinavir [SQV] + minidose ritonavir [r]: steady state [SS] pharmacokinetics [PK] and initial RNA and CD4 response [abstract no. TuPeB4464]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, 383
49. Corbett AH, Eron JJ, Diebold M, et al. Short-term safety and efficacy of an amprenavir (APV)/saquinavir (SQV)/ritonavir (RTV) salvage regimen [abstract no. 450]. 40th Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24-27; Chicago
50. Ribera E, Azuaje C, Montero F, et al. Saquinavir, ritonavir, didanosine, and lamivudine in a once daily regimen for HIV infection in patients with rifampin-containing antituberculosis treatment [poster no. ThPeB7280]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona
51. Veldkamp AI, Hoetlmans RMW, Beijnen JH, et al. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586
52. Gallicano K, Khaliq Y, Carignan G, et al. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001 Aug; 70 (2): 149-58
53. Boyd M, Ruxrungtham K, Zhang X, et al. Enfuvirtide - investigations on the drug interaction potential in HIV-infected patients [poster no. 541]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston
54. Zorrilla CD, Van Dyke R, Bardeguez A, et al. Clinical response, safety, and tolerability to saquinavir-SCG with low-dose ritonavir boosting in combination with zidovudine and lamivudine in HIV-1 infected pregnant women: preliminary results of PACTG 386 [abstract no. 887 and poster no. P-23]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston
55. Gerstoft J, Dragsted UB, Cahn P, et al. Final analysis of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: the MaxCmin1 trial [abstract no. H-172 and poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
56. Saquinavir/r versus indinavir/r: final data from the MaxCmin1 trial. Reports from the 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow. Roche, 2002. (Data on file)
57. Hoffmann-La Roche Inc. Head-to-head HIV study showed significant benefit for boosted saquinavir over boosted indinavir [media release] [online]. Available from URL: http://www.rocheusa.com [Accessed 2002 Jul 18]
58. Dragsted UB, Gerstoft J, Youle M, et al. The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: the MaxCmin2 trial [poster no. PL14.5]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow
59. Saquinavir/r and lopinavir/r go head-to-head: 24-week data from the MaxCmin2 trial. Reports from the 6th International Congress on Drug Therapy in HIV INfection; 2002 Nov 17-21; Glasgow. Roche, 2002. (Data on file)
60. Hoffmann-La Roche Inc. Use of boosted saquinavir or Kaletra(TM) results in HIV suppression in most patients at 24 weeks [media release] [online]. Available from URL: http://www.rocheusa.com [Accessed 2002 Dec 4]
61. Piketty C, Race E, Castiel P, et al. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz [letter]. AIDS 2000; 14 (5): 626-8
62. Piketty C, Trylesinski A, Hill A, et al. Plasma drug levels and resistance as predictors of efficacy for the combination including saquinavir, ritonavir and efavirenz [abstract]. Antiviral Ther 2001; 6 Suppl. 1 : 89
63. Chaillou S, Durant J, Clevenbergh P, et al. Long term efficacy of saquinavir and ritonavir low dosage (baby-dose) in HIV patients failing combination therapy: correlation of response to treatment with genotypic mutations and pharmacologic data [abstract no. 565]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon
64. Montaner JSG, Saag MS, Barylski C, et al. FOCUS study: saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients [abstract no. H-167 and poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
65. Montaner JSG, Saag M, Barylski C, et al. FOCUS study: saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients [abstract no. 1-670 plus oral presentation]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago
66. Cardiello P, Srasuebkul P, Hassink E, et al. The efficacy, safety, and immunological changes of qd saquinavir-soft gel capsules 1600 mg/ritonavir 100 mg plus dual nucleosides in patients who had an undetectable viral load after 3 years of treatment [poster no. 549-T]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle
67. Hoffmann-La Roche Inc. Fortovase with Kaletra shows encouraging results among protease inhibitor-experienced HIV patients in initial study - a second study evaluates viral and immune response of switch to once-daily fortovase with ritonavir from twice-daily Fortovase [media release]. 2002 Mar 1
68. Mars M, Trylesinski A, Loi S, et al. Fortovase-ritonavir (FTV/R) QD used after a first protease inhibitor (PI) therapy in HIV infected patients (pts) with virologic failure [abstract no. 676], 1st International Aids Society Conference; 2001 Jul 8-11; Buenos Aires, 282
69. Wright DP, Pithey C. Virologic improvement in patients receiving once-daily saquinavir/min-dose ritonavir (SQV/r) therapy in clinical practice [abstract no. 328]. Clin Infect Dis 2000 Jul; 31 (1): 269
70. Baril JG, Trottier B, LeBlanc R, et al. Efficacy of switching virologically suppressed patients from a protease inhibitor (PI) based therapy to a saquinavir (SQV) and low dose ritonavir (RTV) once daily dosing regimen with therapeutic drug monitoring (TDM) [poster]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow
71. Baril JG, Trottier B, LeBlanc R, et al. Efficacy of once daily saquinavir (SQV) and low dose ritonavir (RTV) containing salvage therapy in heavily pretreated patients who were not virologically suppressed [poster]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow
72. Staszewski S, Dauer B, Stephan C, et al. Switch to a simple boosted double protease inhibitor regimen of lopinavir/r and saquinavir without reverse transcriptase inhibitors after multiple therapy failures (poster TuPeB4427). Roche, 2002. (Data on file)
73. Ruiz L, Ribera E, Bonjochl A, et al. Virological and immunological benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month follow-up) [poster no. 421-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle
74. Zala C, Patterson P, Coll P, et al. Early antiviral response and safety of a dual boosted protease inhibitors regimen including lopinavir/r (LPV) plus amprenavir (AMP) or Fortovase (FTV) in heavily pretreated HIV infected patients. Roche, 2002. (Data on file)
75. Hoffmann-La Roche Inc. Four studies examine strategy of combining saquinavir with Kaletra (TM) in treatment-experienced HIV patients [media release] [online]. Available from URL: http://www.rocheusa.com [Accessed 2002 Jul 15]
76. Khanlou H, Graham E, Brill M, et al. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy [letter]. AIDS 2002; 16: 797-812
77. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir [letter]? AIDS 2002; 16 (2): 296-7
78. Smith GHR, Klein MB, Murphy T, et al. Double, boosted salvage therapy with lopinavir/ritonavir and saquinavir-sgc in HIV-1 infected patients having failed 3 classes of antiretrovirals. Roche, 2001. (Data on file)
79. Stephan C, Lutz T, Haberl A, et al. Lopinavir/r - saquinavir without RTI in pre-treated patients with NUC associated resistance or toxicity [poster no. LB/P8]. 8th European Conference on Clinical Aspects and treatment of HIV-Infection; 2001 Oct 28-31; Athens
80. Gill MJ. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team [letter]. AIDS 1998 Jul 30; 12 (11): 1400-2
81. Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS 1998 Jul 30; 12 (11): F103-9
82. O'Brien WA, Acosta E, Felizarta F, et al. Switch of saquinavir 400 mg/ritonavir 400 mg to saquinavir 1000 mg/ritonavir 100 mg during BID four drug antiretroviral therapy [poster no. WeOrB1263]. XIV International World AIDS Conference; 2002 Jul 7-12; Barcelona
83. Srasuebkul P, Cardiello P, Hassink E, et al. Gastrointestinal toxicity and triglyceride levels when switching from a twice daily to a once daily saquinavir soft gel regimen. Roche, 2002. (Data on file)
84. Walmsley S, Montaner J, Hill A, et al. NRTI treatment as a risk factor for hyperlipidemia: results from the FOCUS trial [poster]. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2002 Sep 22-25; San Diego
85. Hoffmann-La Roche. Roche-HIV.com/Newsroor/Latest News [online]. Available from URL: http://www.roche-hiv.com [Accessed 2003 Feb 24]
86. British National Formulary. Saquinavir [online]. Available from URL: http://www.bnf.org [Accessed 2003 Feb 7]
87. Blaschke T, Flexner C, Sheiner L, et al. Effect of simultaneous or staggered dosing of saquinavir (SQV), ritonavir (RTV), and nelfinavir (NFV) on pharmacokinetic (PK) interactions [abstract no. 76]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 4; San Francisco
88. Gulick RM, Mellors JW, Havlir D, et al. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000 Jul 4; 133 (1): 35-9
89. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998 Jul 1; 280 (1): 35-41
90. Cameron DW, Angel JB, Ryan J, et al. Durability of ritonavir plus saquinavir dual protease inhibitor therapy in HIV infection: 5-year follow-up [abstract no. 550-T]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle
91. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. 2000 Jan 19; 283: 381-90
92. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998 Jul 25; 352: 314-6
93. European guidelines for the clinical management and treatment of HIV infected adults in Europe 2001 [online]. Available from URL: http://www.iapac.org [Accessed 2003 Feb 20]
94. International Association of Physicians in AIDS Care (IAPAC). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://www.iapac.org [Accessed 2003 Feb 20]
95. World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach [online]. Available from URL: http://www.who.int/hiv/pub [Accessed 2003 Feb 20]
96. Abbott Laboratories. Kaletra prescribing information. Chicago (IL): Abbott Laboratories, 2002
97. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63 (8): 769-805
98. Moyle G. Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens. AIDS Patients Care STDS 2002 Dec; 16 (12): 585-97
99. Haas DW, Zala C, Schrader S, et al. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial A1424-009, week 48) [abstract no. 42]. 9th Conference for Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle